Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318261 | 0.87 | — | — | |
| SCHEMBL9697769 | 0.86 | ALDH1A1 (0.35) | ALDH1A1CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL7869194 | 0.86 | ALDH1A1 (0.38) | ALDH1A1CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL651147 | 0.84 | HCRTR2 (0.38) | HCRTR2GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL28960535 | 0.84 | HCRTR2 (0.38) | HCRTR2GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL24411299 | 0.84 | ALDH1A1 (0.37) | ALDH1A1CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL375444 | 0.84 | ALDH1A1 (0.37) | ALDH1A1CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL12979137 | 0.84 | ALDH1A1 (0.37) | ALDH1A1CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL144302 | 0.84 | ALDH1A1 (0.37) | ALDH1A1CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL142417 | 0.84 | ALDH1A1 (0.37) | ALDH1A1CHRM2CHRM1CHRM3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION GLAXOSMITHKLINE | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | MC4R, MC5R, MC2R | HCRTR2 1636/4885ALDH1A1 4209/4885GPR119 164/4885 |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | MC4R, MC2R, MC3R | HCRTR2 816/4885ALDH1A1 1655/4885GPR119 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.